4//SEC Filing
Espinoza Octavio 4
Accession 0002001011-25-000127
CIK 0000886163other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:19 PM ET
Size
21.3 KB
Accession
0002001011-25-000127
Insider Transaction Report
Form 4
Espinoza Octavio
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-16$52.84/sh+1,194$63,091→ 27,380 total - Exercise/Conversion
Common Stock
2025-12-16$57.22/sh+69$3,948→ 27,449 total - Exercise/Conversion
Common Stock
2025-12-16$63.62/sh+285$18,132→ 27,734 total - Exercise/Conversion
Common Stock
2025-12-16$92.65/sh+652$60,408→ 28,386 total - Exercise/Conversion
Common Stock
2025-12-16$103.42/sh+181$18,719→ 28,567 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-16−1,194→ 972 totalExercise: $52.84Exp: 2032-05-05→ Common Stock (1,194 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-16−69→ 7,171 totalExercise: $57.22Exp: 2030-10-01→ Common Stock (69 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-16−285→ 18,171 totalExercise: $63.62Exp: 2032-12-13→ Common Stock (285 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-16−652→ 2,405 totalExercise: $92.65Exp: 2028-03-02→ Common Stock (652 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-16−181→ 4,186 totalExercise: $103.42Exp: 2031-02-03→ Common Stock (181 underlying)
Footnotes (5)
- [F1]The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter.
- [F2]As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022.
- [F3]Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter.
- [F4]The stock option is fully vested and exercisable.
- [F5]The stock option vests as to 50% of the underlying shares on January 3, 2025 and as to the remaining on February 3, 2025.
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001905248
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 4:19 PM ET
- Size
- 21.3 KB